Beta Bionics, Inc. SEC Filings

Russell Steven Jon, identified as the Chief Medical Officer of Beta Bionics, Inc. (BBNX), reported a sale of 1,015 shares of the issuer's common stock on 09/02/2025. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with individual trade prices ranging from $18.58 to $19.09. After the transaction the reporting person beneficially owned 71,017 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Beta Bionics insider sale to cover taxes on RSU vesting. Chief Product Officer Mike Mensinger sold 1,089 shares of Beta Bionics common stock on 09/02/2025 at a weighted average price of $18.8632, with the transaction price range between $18.58 and $19.09. After the sale, Mensinger beneficially owned 91,815 shares, reported as direct ownership. The filing states the sale was made to satisfy tax withholding obligations tied to restricted stock unit vesting; no option exercises or derivative transactions were reported. The form was signed by an attorney-in-fact on 09/03/2025.

Mark Hopman, identified as the Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported a transaction on 09/02/2025. The filing shows 848 shares of Common Stock were sold to cover tax withholding obligations related to restricted stock unit vesting. The weighted average sale price was $18.8632, with individual sale prices ranging from $18.58 to $19.09. After the reported transaction, Hopman beneficially owned 33,284 shares directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Stephen Feider, identified as an officer (Chief Financial Officer) of Beta Bionics, Inc. (BBNX), reported a sale of common stock on 09/02/2025. The Form 4 shows 1,462 shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with prices ranging from $18.58 to $19.09. After the transaction, Mr. Feider beneficially owned 44,041 shares (reported as direct ownership). The filing is signed by Stephen Feider on 09/03/2025. No derivative transactions or other changes are reported.

Form 144 notice from an insider of Beta Bionics, Inc. (BBNX) indicates a proposed brokered sale of 6,818 common shares through Merrill Lynch on 09/04/2025 to be executed on the NASDAQ. The filing shows the shares were acquired in two transactions: 2,069 shares from an equity award on 09/01/2025 and 4,749 shares from a stock option exercise on 09/04/2025, with payment listed as cash. The issuer's total shares outstanding are stated as 43,470,125, and the aggregate market value of the proposed sale is $136,179.70. The filing also discloses prior sales by the same person during the past three months totaling 16,158 and 868 shares on 08/19/2025 and 06/02/2025, respectively.

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 08/22/2025. He exercised an employee stock option with a $5.10 exercise price to acquire 4,413 shares and immediately sold those 4,413 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $17.014 per share (range $17.00–$17.12). After these transactions his beneficial ownership declined from 49,916 shares to 45,503 shares. The option vests in 48 equal monthly installments beginning 09/14/2023 and expires 09/13/2033.

Form 144 notice for Beta Bionics, Inc. (BBNX) reports a proposed sale of 4,413 shares of common stock through Merrill Lynch on 08/22/2025 with an aggregate market value of $75,082.65. The filing lists total shares outstanding of 43,470,125. The shares to be sold were acquired on 08/22/2025 as stock options from Beta Bionics and the stated payment method is cash. The filing also discloses two prior sales by Stephen Feider on 06/02/2025 (1,497 shares, $26,783.06) and 08/19/2025 (5,587 shares, $95,171.78).

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported coordinated transactions on 08/19/2025 under a Rule 10b5-1 plan adopted May 13, 2025. He exercised an employee stock option with a $5.10 exercise price to acquire 16,158 shares. The same day he sold 16,158 shares pursuant to the 10b5-1 plan at a weighted average sale price of $16.6095, with reported price range of $16.26 to $17.1719. The filing shows beneficial ownership counts of 50,290 shares following the acquisition line and 34,132 shares following the reported sale; the derivative table reports 16,158 option shares underlying and 67,084 total shares beneficially owned following the derivative transaction line. The form is signed by an attorney-in-fact on 08/20/2025.

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions on 08/19/2025. He acquired 5,587 shares via an employee stock option with an exercise price of $5.10 and immediately sold 5,587 shares pursuant to a Rule 10b5-1 plan at a weighted average price of $17.034505 (price range $17.00–$17.095). After these transactions his direct beneficial ownership decreased from 51,090 shares to 45,503 shares. The option shares vest in 48 equal monthly installments measured from September 14, 2023, and the related option lists an exercisable/expiration reference dated 09/13/2033.